$1.41 -0.03 (%) Lexicon Pharmaceuticals Inc - NASDAQ

Sep. 30, 2014 | 04:00 PM

Partner Headlines

  1. Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care

    Benzinga | Sep. 11, 2014 | 16:32PM EST
  2. Benzinga's Top Downgrades

    Benzinga | Aug. 19, 2014 | 09:00AM EST
  3. Gabelli Downgrades Lexicon Pharmaceuticals To Hold

    Benzinga | Aug. 19, 2014 | 08:43AM EST
  4. FOMC To End QE In October; The Container Store Shares Slide

    Benzinga | Jul. 9, 2014 | 15:05PM EST
  5. AeroVironment Surges On Upbeat Results; The Container Store Shares Slide

    Benzinga | Jul. 9, 2014 | 12:27PM EST
  6. Markets Edge Higher; Alcoa Profit Beats Street View

    Benzinga | Jul. 9, 2014 | 10:20AM EST
  7. Morning Market Movers

    Benzinga | Jul. 9, 2014 | 09:42AM EST
  8. US Stock Futures Flat; All Eyes On Fed Minutes

    Benzinga | Jul. 9, 2014 | 07:40AM EST
  9. Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes

    Benzinga | Jul. 9, 2014 | 07:03AM EST
  10. 3 Small-Cap Biotechs That Institutions Are Loving

    Benzinga | Jul. 7, 2014 | 14:54PM EST
  11. Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat Estimates

    Benzinga | Apr. 14, 2014 | 10:17AM EST
  12. Morning Market Movers

    Benzinga | Apr. 14, 2014 | 09:38AM EST
  13. US Stock Futures Flat; Citigroup Earnings In Focus

    Benzinga | Apr. 14, 2014 | 07:43AM EST
  14. Benzinga's Top Initiations

    Benzinga | Dec. 6, 2013 | 08:14AM EST
  15. UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, Says Asset Overvalued

    Benzinga | Dec. 6, 2013 | 07:19AM EST
  16. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 3, 2013 | 08:43AM EST
  17. Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo and LX1033 were Not Statistically Significant

    Benzinga | Dec. 3, 2013 | 06:07AM EST
  18. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 9, 2013 | 08:20AM EST
  19. Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves Primary Objective Demonstrating Safety, Tolerabilty

    Benzinga | Oct. 9, 2013 | 06:05AM EST
  20. Market Wrap For Tuesday, October 1: Government Down, Markets Up

    Benzinga | Oct. 1, 2013 | 16:36PM EST
  21. Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues

    Benzinga | Oct. 1, 2013 | 15:17PM EST
  22. Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge

    Benzinga | Oct. 1, 2013 | 13:24PM EST
  23. Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%

    Benzinga | Oct. 1, 2013 | 10:48AM EST
  24. Morning Market Movers

    Benzinga | Oct. 1, 2013 | 09:47AM EST
  25. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 1, 2013 | 08:39AM EST
  26. Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, Says There Were No Serious Adverse Events

    Benzinga | Oct. 1, 2013 | 06:48AM EST
  27. Lexicon Pharmaceuticals Provides Clinical Pipeline Update

    Benzinga | Jul. 30, 2013 | 06:24AM EST
  28. Stocks Surge as Fiscal Cliff Deal Appears Close

    Benzinga | Dec. 31, 2012 | 09:46AM EST
  29. Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise

    Benzinga | Dec. 31, 2012 | 06:10AM EST
  30. Mid-Morning Market Update: Markets Rise Ahead of Fiscal Cliff, Cott Falls

    Benzinga | Dec. 31, 2012 | 03:47AM EST
  31. Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets

    Benzinga | Dec. 17, 2012 | 04:31AM EST
  32. Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1033 for IBS

    Benzinga | Dec. 17, 2012 | 00:50AM EST
  33. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 7, 2012 | 03:05AM EST
  34. Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved

    Benzinga | Nov. 6, 2012 | 03:34AM EST
  35. Lexicon Prices 17.5M Shares At $2.25 per Share

    Benzinga | Oct. 18, 2012 | 03:27AM EST
  36. Lexicon Announces Proposed Common Stock Offering

    Benzinga | Oct. 17, 2012 | 10:14AM EST
  37. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 16, 2012 | 02:15AM EST
  38. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 12, 2012 | 02:15AM EST
  39. A Peek Into The Market Before The Trading Starts

    Benzinga | Oct. 12, 2012 | 01:16AM EST
  40. A Peek Into The Market Before The Trading Starts

    Benzinga | Aug. 16, 2012 | 01:19AM EST
  41. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies

    Benzinga | Aug. 16, 2012 | 00:07AM EST
  42. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 2, 2012 | 13:29PM EST
  43. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results

    Benzinga | Jul. 31, 2012 | 00:37AM EST
  44. A Peek Into The Market Before The Trading Starts

    Benzinga | Jun. 29, 2012 | 01:21AM EST
  45. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics

    Benzinga | Jun. 29, 2012 | 00:36AM EST
  46. SBA Communications Corporation, The Ryland Group Among Stocks Hitting 52-Week Highs Tuesday

    FoxBusiness | Jun. 26, 2012 | 10:32AM EST
  47. Teva Pharmaceutical Industries, Constellation Brands Among Stocks Up on High Volume Monday

    FoxBusiness | Jun. 25, 2012 | 06:33AM EST
  48. Benzinga's Top Pre-Market Gainers

    Benzinga | Jun. 25, 2012 | 02:09AM EST
  49. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes

    Benzinga | Jun. 25, 2012 | 00:55AM EST
  50. LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

    Benzinga | Jan. 9, 2012 | 09:30AM EST
Trading Center